Market closedNon-fractional

Foghorn Therapeutics/FHTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Foghorn Therapeutics

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Ticker

FHTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

116

FHTX Metrics

BasicAdvanced
$293M
Market cap
-
P/E ratio
-$2.21
EPS
3.15
Beta
-
Dividend rate
$293M
3.15
4.063
3.969
-35.196
-44.087
-20.46%
152.29%
6.587
-2.33
-2.33
-1.909
64.41%
-18.18%
261.75%
-18.69%

What the Analysts think about FHTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

FHTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-500.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5M
-12.28%
Net income
-$25M
3.73%
Profit margin
-500.00%
18.26%

FHTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.87%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.34
-$0.57
-$0.59
-
Expected
-$0.74
-$0.75
-$0.76
-$0.63
-$0.66
Surprise
-4.76%
-54.65%
-25.31%
-6.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Foghorn Therapeutics stock?

Foghorn Therapeutics (FHTX) has a market cap of $293M as of July 06, 2024.

What is the P/E ratio for Foghorn Therapeutics stock?

The price to earnings (P/E) ratio for Foghorn Therapeutics (FHTX) stock is 0 as of July 06, 2024.

Does Foghorn Therapeutics stock pay dividends?

No, Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Foghorn Therapeutics dividend payment date?

Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Foghorn Therapeutics?

Foghorn Therapeutics (FHTX) has a beta rating of 3.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Foghorn Therapeutics stock

Buy or sell Foghorn Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing